Skip to main
VANI
VANI logo

VANI Stock Forecast & Price Target

VANI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivani Medical Inc. is positioned favorably due to the promising potential of its product NPM-139, which may enhance the safety and tolerability of existing therapies like semaglutide, potentially reducing discontinuation rates associated with side effects. The encouraging data supporting NPM-139, including its ability to facilitate approximately 20% weight loss sustained over six months, bolsters the outlook for advancing the product into clinical development. Additionally, the company's innovative NanoPortal technology aims to improve patient dosing compliance, further contributing to a robust pipeline as it addresses chronic disease treatment challenges.

Bears say

Vivani Medical Inc faces significant risks that contribute to a negative outlook, particularly surrounding the development of its lead product, NPM-139. Key concerns include the potential failure of NPM-139 in clinical trials, the possibility of not obtaining regulatory approval, and challenges in achieving commercial success due to factors such as market size and competition. Additionally, the risk of dilution may further impact investor confidence and financial stability, exacerbating the company's precarious position in the biopharmaceutical sector.

VANI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivani Medical Inc (VANI) Forecast

Analysts have given VANI a Strong Buy based on their latest research and market trends.

According to 1 analysts, VANI has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivani Medical Inc (VANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.